These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6779315)

  • 41. The effect of haloperidol feeding on dopamine receptor number in ten mouse strains.
    Belmaker RH; Bannet J; Brecher-Fride E; Yanai J; Ebstein RP
    Clin Genet; 1981 May; 19(5):353-6. PubMed ID: 7296924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic nicotine use blocks haloperidol-induced increase in striatal D2-dopamine receptor density.
    Prasad C; Spahn SA; Ikegami H
    Biochem Biophys Res Commun; 1989 Feb; 159(1):48-52. PubMed ID: 2522303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ex vivo 3H-spiroperidol binding to rat striatum and the inhibitory effects of neuroleptics.
    Nakajima T; Egawa E; Kuruma I
    Jpn J Pharmacol; 1981 Apr; 31(2):159-64. PubMed ID: 6118446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation.
    Chivers JK; Reavill C; Jenner P; Marsden CD
    J Pharm Pharmacol; 1988 Sep; 40(9):613-9. PubMed ID: 2907027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine receptor changes after long-term haloperidol treatment in rats.
    Ebstein RP; Pickholz D; Belmaker RH
    J Pharm Pharmacol; 1979 Aug; 31(8):558-9. PubMed ID: 40001
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sensitive periods for the effect of haloperidol on development of striatal dopamine receptors.
    Rosengarten H; Friedman E; Friedhoff AJ
    Birth Defects Orig Artic Ser; 1983; 19(4):511-3. PubMed ID: 6871420
    [No Abstract]   [Full Text] [Related]  

  • 48. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
    Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
    Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between dopamine receptor occupation by spiperone and acetylcholine levels in the rat striatum after long-term haloperidol treatment depends on dopamine innervation.
    Korf J; Sebens JB
    J Neurochem; 1987 Feb; 48(2):516-21. PubMed ID: 2878979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration.
    Owen F; Cross AJ; Waddington JL; Poulter M; Gamble SJ; Crow TJ
    Life Sci; 1980 Jan; 26(1):55-9. PubMed ID: 7189005
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of long-term dosing with tiapride on brain dopamine receptors and metabolism in rats. Comparative study with sulpiride and haloperidol.
    Satoh H; Kuwaki T; Shirakawa K; Kohjimoto Y; Ono T; Shibayama F; Nomura Y
    Jpn J Pharmacol; 1987 Aug; 44(4):393-403. PubMed ID: 3682405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of timiperone on 3H-spiroperidol binding to rat striatal dopamine receptors.
    Tachizawa H; Sudo K; Sano M
    Eur J Pharmacol; 1979 Nov; 59(3-4):245-51. PubMed ID: 43256
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of lead exposure on dopaminergic receptors in rat striatum and nucleus accumbens.
    Govoni S; Lucchi L; Missale C; Memo M; Spano PF; Trabucchi M
    Brain Res; 1986 Aug; 381(1):138-42. PubMed ID: 3756492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aging and the regulation of striatal dopaminergic mechanisms in mice.
    Randall PK; Severson JA; Finch CE
    J Pharmacol Exp Ther; 1981 Dec; 219(3):695-700. PubMed ID: 7197719
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops.
    Kinon BJ; Kane JM
    Psychopharmacology (Berl); 1989; 98(4):465-71. PubMed ID: 2505286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex.
    Meller E; Bohmaker K; Rosengarten H; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Sep; 37(3):323-32. PubMed ID: 7178646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exogenous l-dopa alters spiroperidol binding, in vivo, in the mouse striatum.
    De Jesus OT; Van Moffaert GJ; Dinerstein RJ; Friedman AM
    Life Sci; 1986 Jul; 39(4):341-9. PubMed ID: 3736329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prenatal haloperidol alters striatal dopamine and opiate receptors.
    Moon SL
    Brain Res; 1984 Dec; 323(1):109-13. PubMed ID: 6098328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade.
    Traub M; Reches A; Wagner HR; Fahn S
    Neurosci Lett; 1986 Oct; 70(2):245-9. PubMed ID: 2946007
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
    Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
    Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.